AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Last update at 2024-04-24T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -14.02200M | -18.57000M | -2.95800M | -2.37063M | -2.56000M |
| Minority interest | - | - | - | - | - |
| Net income | -14.01456M | -18.53148M | -2.93834M | -2.37512M | -2.56000M |
| Selling general administrative | 4.99M | 3.58M | 2.20M | 1.64M | 1.65M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.08M | 0.39M | 1.82M | 1.18M | 0.96M |
| Reconciled depreciation | 0.06M | 0.04M | 0.02M | 0.00835M | 0.02M |
| Ebit | -14.08528M | -18.78452M | -2.83666M | -2.37249M | -2.58280M |
| Ebitda | -14.02900M | -18.74600M | -2.81700M | -2.35778M | -2.56300M |
| Depreciation and amortization | 0.06M | 0.04M | 0.02M | 0.01M | 0.02M |
| Non operating income net other | - | - | 0.00227M | - | - |
| Operating income | -14.02900M | -18.74600M | -2.81700M | -2.37249M | -2.56300M |
| Other operating expenses | 14.11M | 19.13M | 4.64M | 3.55M | 3.53M |
| Interest expense | -0.05684M | 0.00129M | 0.14M | 0.00449M | 0.00259M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.00744M | 0.00474M | 0.00227M | 0.00636M | 0.00521M |
| Net interest income | 0.00744M | 0.00345M | -0.14125M | 0.00186M | 0.00262M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.00744M | -0.03852M | -0.01966M | 0.00449M | 0.00521M |
| Total revenue | 0.08M | 0.39M | 1.82M | 1.18M | 0.96M |
| Total operating expenses | 14.11M | 19.13M | 4.64M | 3.55M | 3.53M |
| Cost of revenue | - | - | - | 1.91M | -0.00020M |
| Total other income expense net | 0.00700M | 0.18M | -0.14100M | 0.00186M | 0.00300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -14.02112M | -18.57000M | -2.95807M | -2.37063M | -2.56009M |
| Net income applicable to common shares | -14.02112M | -18.57032M | -2.95807M | -2.37063M | -2.56009M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 31.35M | 11.80M | 10.39M | 0.47M | 0.64M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.33M | 0.20M | 0.35M | 0.10M | 0.36M |
| Total liab | 4.75M | 7.43M | 0.82M | 2.04M | 1.66M |
| Total stockholder equity | 26.60M | 4.36M | 9.57M | -1.57456M | -1.02200M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3.00M | 3.38M | 0.36M | 1.85M | 1.24M |
| Common stock | 0.03M | 0.00638M | 0.00383M | 0.00030M | 0.22M |
| Capital stock | 0.03M | 0.00638M | 0.08M | 1.93M | 2.19M |
| Retained earnings | -78.39702M | -64.37590M | -45.80558M | -42.84751M | -40.47688M |
| Other liab | - | 2.00M | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 2.17M | 0.01M | 0.01M | 0.01M | 0.01M |
| Cash | 27.61M | 11.42M | 9.88M | 0.28M | 0.26M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.75M | 5.44M | 0.81M | 2.02M | 1.62M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -27.61300M | -11.42400M | -9.68594M | -0.24360M | 0.04M |
| Short term debt | - | - | 0.18M | 0.01M | 0.26M |
| Short long term debt | - | - | 0.18M | 0.01M | 0.26M |
| Short long term debt total | - | - | 0.20M | 0.04M | 0.30M |
| Other stockholder equity | 104.97M | 68.73M | 55.29M | 39.34M | 37.93M |
| Property plant equipment | 0.23M | 0.16M | 0.15M | 0.01M | 0.01M |
| Total current assets | 28.94M | 11.63M | 10.23M | 0.45M | 0.62M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 26.60M | 4.36M | 9.49M | -3.50699M | -2.99368M |
| Short term investments | - | - | - | - | - |
| Net receivables | - | 0.05M | 0.18M | 0.07M | 0.12M |
| Long term debt | - | - | 0.01M | 0.03M | 0.04M |
| Inventory | - | -0.04901M | -0.18266M | - | -0.12181M |
| Accounts payable | 1.75M | 2.06M | 0.27M | 0.15M | 0.13M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -0.51170M | - | -0.66325M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00383M | 0.00030M | 0.22M |
| Preferred stock total equity | - | - | 0.08M | - | - |
| Retained earnings total equity | - | - | -45.80558M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.17M | 0.01M | 0.01M | 0.01M | 0.01M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2.41M | 0.17M | 0.16M | 0.02M | 0.02M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.13426M | -0.04772M | -0.15679M | -0.00761M | 0.00000M |
| Change to liabilities | -2.68747M | 6.81M | 0.14M | 0.64M | 0.55M |
| Total cashflows from investing activities | -0.13426M | -0.04772M | -0.15679M | -0.00761M | -0.00761M |
| Net borrowings | - | -0.02786M | 1.05M | -0.01026M | 0.30M |
| Total cash from financing activities | 35.35M | 12.78M | 12.51M | 1.43M | 1.49M |
| Change to operating activities | -3.32898M | -0.01627M | -0.02470M | -0.05621M | 0.04M |
| Net income | -14.02112M | -18.57032M | -2.95807M | -2.37063M | -2.56009M |
| Change in cash | 16.19M | 1.54M | 9.60M | 0.02M | -0.05303M |
| Begin period cash flow | 11.42M | 9.88M | 0.28M | 0.26M | 0.31M |
| End period cash flow | 27.61M | 11.42M | 9.88M | 0.28M | 0.26M |
| Total cash from operating activities | -19.03021M | -11.19642M | -2.75057M | -1.39850M | -1.54303M |
| Issuance of capital stock | 27.73M | 9.41M | 11.46M | 1.44M | 1.19M |
| Depreciation | 0.06M | 0.04M | 0.02M | 0.00835M | 0.02M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.05M | 0.13M | -0.11406M | 0.05M | -0.06206M |
| Sale purchase of stock | 0.00000M | -0.00100M | 11.46M | 1.44M | 1.19M |
| Other cashflows from financing activities | 7.63M | 3.40M | 1.36M | -0.00761M | -1188.51000M |
| Change to netincome | 0.90M | 0.41M | 0.06M | 0.33M | 0.47M |
| Capital expenditures | 0.13M | 0.05M | 0.16M | 0.00761M | 0.00761M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 9.60M | - | - |
| Change in working capital | -5.96744M | 6.93M | -0.00081M | 0.64M | 0.53M |
| Stock based compensation | 0.90M | 0.37M | 0.06M | 0.33M | 0.47M |
| Other non cash items | - | 0.04M | 0.12M | 1.20M | 1.17M |
| Free cash flow | -19.16447M | -11.24414M | -2.90736M | -1.40610M | -1.54303M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs Inc |
- -% | 1.54 | - | 10.63 | 59.01 | 0.93 | 4.15 | 0.17 |
| NVO Novo Nordisk A/S |
-2.48 1.93% | 126.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.58 1.23% | 126.80 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.15 1.02% | 400.76 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-0.61 0.67% | 90.10 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
1900 Lake Park Drive, Smyrna, GA, United States, 30080
| Name | Title | Year Born |
|---|---|---|
| Mr. David Alan Dodd | Chairman, Pres & CEO | 1950 |
| Mr. Mark W. Reynolds CPA, CPA | CFO & Corp. Sec. | 1962 |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer | 1955 |
| Dr. Harriet Latham Robinson | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board | 1938 |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer | 1950 |
| Jeffrey Welch | Head of Process Devel. & Manufacturing Operations | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...